Document Detail


Gene therapy progress and prospects: in tissue engineering.
MedLine Citation:
PMID:  16177815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Tissue engineering (TE) has existed for several years as an area spanning many disciplines, including medicine and engineering. The use of stem cells as a biological basis for TE coupled with advances in materials science has opened up an entirely new chapter in medicine and holds the promise of major contributions to the repair, replacement and regeneration of damaged tissues and organs. In this article, we review the spectrum of stem cells and scaffolds being investigated for their potential applications in medicine.
Authors:
J Polak; L Hench
Related Documents :
2694375 - Update on molar pregnancy and choriocarcinoma.
10246185 - Deficiencies in efficiency.
17701875 - Intracerebral hemorrhage.
3895205 - The management of liver trauma.
3459715 - Group practice in the netherlands.
14994835 - Time: a vital resource.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gene therapy     Volume:  12     ISSN:  0969-7128     ISO Abbreviation:  Gene Ther.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-06     Completed Date:  2006-03-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9421525     Medline TA:  Gene Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1725-33     Citation Subset:  IM    
Affiliation:
Tissue Engineering and Regenerative Medicine Centre, Imperial College London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Bioreactors
Bone Substitutes
Forecasting
Gene Therapy / methods,  trends*
Humans
Models, Animal
Regeneration
Stem Cell Transplantation
Stem Cells
Tissue Engineering / methods,  trends*
Chemical
Reg. No./Substance:
0/Bone Substitutes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of psychosocial factors of noncompliance in hypertensive patients.
Next Document:  Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector s...